FDA declined to approve Merck’s claim that its cholesterol-lowering drugs Zetia and Vytorin reduce the risk of heart attacks and strokes in patients with coronary heart disease.
FDA declined to approve Merck’s claim that its cholesterol-lowering drugs Zetia and Vytorin reduce the risk of heart attacks and strokes in patients with coronary heart disease.
While Zetia and Vytorin are indicated for use along with a healthy diet to reduce elevated LDL cholesterol in patients with hyperlipidemia, the effect of Zetia on cardiovascular morbidity and mortality “has not been determined” by FDA, according to a Merck statement.
Related: FDA panel recommends approving Repatha, Praluent to lower cholesterol
In addition, “no incremental benefit of Vyotrin on cardiovascular morbidity and mortality over and above that demonstrated for simvastatin [Zocor] has been established”, according to the statement.
FDA's decision follows a recommendation in December by one of its advisory committees that Merck should not be allowed to claim that Vytorin (ezetimibe/simvastatin) reduces the risk of heart attacks and strokes in patients with coronary heart disease, according to Reuters.
Related: Battle of the cholesterol drugs expected
Merck based its applications for the claims on the results of data from its 18,000-patient Improve-IT study. The study showed that Vytorin, a combination of the off-patent statin drug simvastatin with the active ingredient in Zetia, ezetimibe, beat simvastatin alone at cutting cardiovascular risks by 6.4%.
However, FDA reviewers noted that the reduction in risk was small and limited to certain types of patients, such as the elderly and diabetics.
FDA and EMA Accepts Applications for New Nusinersen Regimen
January 23rd 2025An investigational higher dose of spinal muscular atrophy drug nusinersen gains attention as the FDA and European Medicines Agency (EMA) considerate it as an alternative than the current lower FDA-approved dosage.
Read More